Nachrichten zur Eli Lilly & Co Aktie

Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?

These two healthcare leaders have a long history of competing against one another.…

Should You Buy Eli Lilly Stock Now or Wait for a Dip?

Eli Lilly has experienced robust growth, but investors may be thinking twice about the stock due to its high valuation.…

3 Reasons to Buy Eli Lilly Stock Like Theres No Tomorrow

Eli Lilly is winning the GLP-1 race right now, but it isnt resting on its laurels.…

Eli Lilly: The Macro Health Crisis Is Still Undervalued

…

Drugmakers race to find a place in the next wave of obesity drugs

Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.…

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -2.41% move from the…

Mainzer Ministerpräsident sucht Verbündete für Erhalt von Pharmastandort

MAINZ (dpa-AFX) - Ministerpräsident Gordon Schnieder (CDU) sorgt sich um den Pharmastandort Rheinland-Pfalz. "Die Pharmawirtschaft ist…

Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Some employers are planning to drop coverage of GLP-1 drugs for weight loss next year as more people take the…

Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon

Eli Lilly has solidified its leading position in the booming market for obesity drugs ahead of a wave of possible…

Eli Lilly: Bears Are Missing The Underlying Thesis

…

Can Eli Lillys Clinical Momentum Keep the Stock at Record Highs?

LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering…

Eli Lilly stärkt GLP-1-Führungsanspruch – Foundayo übertrifft orales Semaglutid!

Eli Lilly treibt sein Wachstum durch die globale Dominanz im Markt für Inkretin-Medikamente mit Mounjaro und Zepbound voran. Phase-3-Daten…

Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?

Infectious disease could fuel Eli Lillys next growth phase.…

Jim Cramer says he cant sell Eli Lilly despite its massive run up. Heres why

"I think the majority view is that Lilly is pulling away, kind of Secretariat-like," Jim Cramer said Monday.…

A Weight-Loss Rival Just Crashed 23%. Why Thats Great News for Eli Lilly and Novo Nordisk.

Zealand Pharmas stock is cratering today after disappointing results from a late-stage trial of its GLP-1 dual-receptor agonist drug.…

Zacks Investment Ideas feature highlights: Eli Lilly and Merck

Health cares seasonal strength and defensive appeal are in focus, with Eli Lillys growth and Mercks pipeline progress highlighted as…

Novo Nordisk Real-World Data Supports Ozempic Against LLYs Mounjaro

NVO says real-world data show Ozempic 2 mg matches Eli Lillys Mounjaro on glucose control and is linked to a…

Eli Lillys $12.8 billion obesity bet faces new Medicare test

Eli Lilly (LLY) investors have been struggling to answer a deceptively straightforward question for the last two years. How big…

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors…

Eli Lilly überzeugt mit Studiendaten zu Foundayo und Retatrutide – Aktie legt über 4 % zu!

  Die FDA-Zulassung für Foundayo als erste GLP-1-Pille ohne Nüchternvorgaben überzeugt auch bei Frauen in jeder Phase der Menopause. Der…

Erst gelockt, dann verschreckt – Deutschlands Pharma-Dilemma

Die Pharmaunternehmen Eli Lilly und Boehringer Ingelheim wollen ihre Investitionen hierzulande drastisch kürzen. Sie begründen dies mit den Sparplänen der…

Wall Street sees huge upside as Novo Nordisk backs biotech company

Veru (VERU) stock has not been easy to own. The little biotech has spent years persuading investors that its experimental…

Expertin sieht 'deutliche Warnschüsse' für Pharmastandort

KÖLN (dpa-AFX) - Die von den Pharmariesen Eli Lilly und Boehringer Ingelheim abgesagten Investitionen zeigen…

Eli Lilly reports broad benefits for experimental obesity drug retatrutide

…

Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide

Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide…

Eli Lillys $3.8 Billion Vaccine Bets: Heres the Big Story Many Investors Are Missing

Eli Lilly just announced a trio of acquisitions that will allow it to build a new business focused on infectious…

Eli Lilly makes surprising retreat from major market

Eli Lillys (LLY) chairman and CEO Dave Ricks told German business newspaper Handelsblatt that Lilly would halve its planned investment…

Prediction: Eli Lilly Will Reach $1,200 in 2026

International growth could help push Lilly even higher.…

Novos Wegovy Pill Isnt Just Beating Expectations -- Its Obliterating Them. Is the Beaten-Down Stock a Buy Now?

Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake.…

Pharmakonzerne kürzen Investitionen - Bund verteidigt Kurs

BERLIN (dpa-AFX) - Die Bundesregierung hat sich zum Stopp von milliardenschweren Pharmainvestitionen in Deutschland geäußert. Eine…

CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors

Its another step in Eli Lillys quest to cement its lead in the chronic weight management market.…

HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropics AI Leap As Lilly, WeightWatchers Turn Up The Heat

Shares of Hims & Hers Health, Inc. (HIMS) slipped 1% in overnight trading heading into Friday as investors weighed rising…

LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues?

Eli Lilly stock gains 14% in a month as strong Q1 results, obesity drug coverage expansion and promising retatrutide data…

Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success

Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.…

Forget Weight Loss Drugs: Here Is Another Reason to Buy Eli Lilly Stock

Eli Lilly is far from a one-trick pony.…

Top Analyst Reports for Berkshire Hathaway, Eli Lilly & Walmart

Berkshire Hathaway, Eli Lilly and Walmart headline new analyst reports, highlighting growth drivers, opportunities and key risks shaping their outlooks.…

ROUNDUP 2: Eli Lilly und Boehringer streichen Investitionen

(neu: Stellungnahmen von Schnieder, Ebling und Schweitzer) ALZEY/INGELHEIM (dpa-AFX) - Für den Wirtschaftsstandort…

ROUNDUP: Eli Lilly und Boehringer streichen Investitionen

ALZEY/INGELHEIM (dpa-AFX) - Deutliches Signal Richtung Berlin: Die Pharmakonzerne Eli Lilly und Boehringer Ingelheim streichen…

Eli Lilly halbiert Milliardeninvestition in Rheinland-Pfalz

ALZEY/INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Eli Lilly will wegen der Sparpläne der Bundesregierung im Gesundheitswesen…

Eli Lillys top dealmaker says dont be surprised to see more M&A that pushes Lilly into new areas

Eli Lillys new top dealmaker explains how the company changed its approach to M&A now that its the most valuable…

Eli Lilly Just Proved Gene Editing Could Be Pharmas Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out

Eli Lillys pipeline is an embarrassment of riches.…

Eli Lilly scores a first in major pharma milestone

Eli Lilly (LLY) just did something worth paying attention to. With CVS Caremark announcing coverage of both Zepbound and newly…

These 8 Words From Eli Lillys CEO Have Wall Street Turning Bullish

David Ricks was addressing the pharmaceutical titans latest hot product.…

Is Eli Lilly Starting an Nvidia-Style Run?

Lilly shares soared more than 18% in May.…

Eli Lilly sends strong message on vaccine strategy

Shingles is no minor inconvenience. Ask anyone who has had it and they will tell you the burning, nerve-rattling pain…

Lillys New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Heres What It Means for Investors

Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner.…

LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?

Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising…

Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

Novo Nordisk lost its lead in the GLP-1 race, but Eli Lillys valuation is a bit rich.…

CVS to restore coverage of Zepbound, add Eli Lillys obesity pill to drug plans

CVS will add Zepbound coverage on Oct. 1, and start covering Lillys newly approved Foundayo pill on June 1.…

Eli Lilly stock gains after CVS adds Zepbound to drug list

Eli Lilly stock gains after CVS adds Zepbound to drug list…